
Sign up to save your podcasts
Or


Vidcast: https://youtu.be/nbwuw_LkAmg
The much touted hydroxychloroquine or HCQ does not appear to reduce infection severity or save lives. This according to a newly pre-published French study of 181 patients with CoVid19 pneumonia.
The data shows that 20% of HCQ-treated patients versus 22% of non-treated patients required ICU care or died with 7 days of admission. Twenty-seven percent of treated patients versus 24% of the untreated developed acute respiratory distress syndrome or ARDS. Three percent of HCQ-treated patients versus 4% of untreated died. Nearly 10% of HCQ-treated patients stopped the drug due to cardiac complications.
More data will be forthcoming. Just know that HCQ appears not to be a silver bullet.
https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1.full.pdf
#covid19 #coronavirus #hydroxychloroquine
By Howard G. Smith MD, AMVidcast: https://youtu.be/nbwuw_LkAmg
The much touted hydroxychloroquine or HCQ does not appear to reduce infection severity or save lives. This according to a newly pre-published French study of 181 patients with CoVid19 pneumonia.
The data shows that 20% of HCQ-treated patients versus 22% of non-treated patients required ICU care or died with 7 days of admission. Twenty-seven percent of treated patients versus 24% of the untreated developed acute respiratory distress syndrome or ARDS. Three percent of HCQ-treated patients versus 4% of untreated died. Nearly 10% of HCQ-treated patients stopped the drug due to cardiac complications.
More data will be forthcoming. Just know that HCQ appears not to be a silver bullet.
https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1.full.pdf
#covid19 #coronavirus #hydroxychloroquine